Learn more about whether Ionis Pharmaceuticals, Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's ...

Morgan Stanley lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $52 from $55 and keeps an Equal Weight rating on the shares.

In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a ...

Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer ...

Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...

Learn more about whether Alvotech or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14 th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical ...

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...